jump to content jump to footer

Streamline Prostate Cancer Screenings with Prostate.Carcinoma.ai in mint Lesion

The Prostate.Carcinoma.ai plug-in, developed by our partner FUSE-AI, is a powerful addition to mint Lesion, designed specifically to enhance prostate cancer screenings. This advanced solution leverages artificial intelligence to automate and accelerate prostate MR evaluations based on the PI-RADS 2.1 guidelines, transforming the workflow and precision for radiologists.

At the click of a button, Prostate.Carcinoma.ai performs full segmentation of the prostate and its anatomical zones, and detects and segments potentially malignant lesions. mint Lesion maps each finding onto the standardized prostate lesion scheme, eliminating the need for time-consuming manual lesion annotation and drawing.

Radiologists maintain full control over the AI-generated results, with the ability to review, reject, modify, or add new findings to ensure accuracy. Based on these inputs, mint Lesion automatically calculates the PI-RADS score, delivering a comprehensive and structured report.

mint Lesion also enables longitudinal tracking of prostate lesions for MRI-based active surveillance. Radiologists can easily monitor changes in lesions over time, supporting informed decision-making for patient management and enhancing the continuity of care.

mint Lesion: lesion categorization under the radiologic recurrence criteria for adjuvant trials
Radiologic recurrence criteria for adjuvant clinical trials in bladder cancer
Radiologic Recurrence Criteria for Adjuvant Clinical Trials in Bladder Cancer
After radical surgery, there is no measurable disease left to follow. A consensus framework defines when a finding on a surveillance scan counts as…
Read more
Radiologist reviewing a glioma MRI case in mint Lesion, with AI-based brain tumor segmentation from Snke (in development)
Consistent Glioma MRI Reporting with mint Lesion
In neuro-oncology, imaging assessments directly shape treatment decisions. For example, under RANO 2.0, whether a follow-up MRI is classified as…
Read more
Representatives of Mint Medical and Curagita shaking hands to mark their lung cancer screening partnership
Curagita and Mint Medical are building a quality- and data-secure infrastructure for the new lung cancer screening program together with 25 outpatient radiology screening sites and two second-read centers. Curagita's CuraHub and Mint Medical's mint Lesion software provide the technical foundation for structured reporting, second reads, and the integration of AI solutions such as contextflow's ADVANCE Chest CT.
Lung cancer screening: cooperation for efficient processes and digital networking
Heidelberg, September 15, 2026 – In close collaboration with two second-reader centers in Heidelberg and 25 outpatient radiology screening providers,…
Read more
scroll-top